Meta Platforms Cuts Equity Awards Again Amid Massive AI Investment Push 
Trump Administration Sues Harvard Over Alleged Race-Based Admissions Practices 
Boeing Secures 50 737 MAX Jet Order from Vietnam Airlines Amid Expanding Global Demand 
Newly Released DOJ Epstein Files Expose High-Profile Connections Across Politics and Business 
U.S. Lawmakers to Review Unredacted Jeffrey Epstein DOJ Files Starting Monday 
Federal Court Fines Mobil Oil Australia A$16 Million for Misleading Fuel Claims 
Bill Gates Pulls Out of India’s AI Impact Summit Amid Controversy and Event Mismanagement 
Qualcomm to Invest $150 Million in India AI Startups, Strengthening Presence in Growing Market 
Yotta to Build $2 Billion AI Data Centre Hub in India with Nvidia Blackwell Ultra Chips 
Mark Zuckerberg Testifies in Youth Social Media Addiction Trial Over Instagram Policies 
NAB Shares Hit Record High as First-Quarter Cash Earnings Jump 16% 
YouTube Outage Disrupts Thousands Worldwide as Recommendation System Fails 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Amazon Surpasses Walmart in Annual Revenue, Signaling a New Era in Retail Competition 
Microsoft Plans $50 Billion AI Investment to Accelerate Growth in the Global South 
Texas Attorney General Ken Paxton has filed a lawsuit against pharmaceutical giant Sanofi, accusing the company of unlawfully incentivizing healthcare providers to prescribe its medications instead of competing alternatives. According to the attorney general’s office, Sanofi allegedly created service-based programs for healthcare professionals that effectively functioned as bribes, in violation of the Texas Health Care Program Fraud Prevention Act.
State officials claim these programs were designed to improperly influence prescribing decisions, potentially impacting fair competition and patient care within Texas healthcare programs. The lawsuit seeks more than $1 million in monetary relief, including civil penalties, as well as a court injunction to prevent any further alleged unlawful conduct.
Sanofi has strongly denied the allegations. In a public statement, the company asserted that its services are fully structured to comply with both federal and state regulations. Sanofi emphasized that the programs are intended to support patient care and improve health outcomes, not to sway physicians’ prescribing behavior. The company also stated that the state’s legal action does not reflect the merits of the case and confirmed it will vigorously defend itself in court.
This is not the first time Attorney General Paxton has taken legal action against major pharmaceutical companies. Previously, Texas sued Sanofi and Bristol-Myers Squibb, alleging they failed to disclose that their blood thinner Plavix was less effective for certain patients. In a separate case last year, the state filed a lawsuit against Eli Lilly, accusing the drugmaker of bribing healthcare providers to prescribe its top-selling medications, including GLP-1 drugs Mounjaro and Zepbound.
The latest lawsuit highlights Texas’ continued scrutiny of pharmaceutical industry practices, particularly regarding alleged healthcare fraud, drug marketing tactics, and compliance with state healthcare laws.
